Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference

GlobeNewswire June 13, 2017

ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial

GlobeNewswire June 8, 2017

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

GlobeNewswire May 31, 2017

ProQR Announces Results for the First Quarter of 2017

GlobeNewswire May 17, 2017

ProQR remembers co-founder Henri Termeer after his unexpected passing

GlobeNewswire May 15, 2017

ProQR Announces R&D Day in New York on June 15

GlobeNewswire May 9, 2017

ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

GlobeNewswire May 1, 2017

ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

GlobeNewswire April 27, 2017

ProQR to Present at the Deutsche Bank Health Care Conference

GlobeNewswire April 20, 2017

ProQR Announces Annual Meeting of Shareholders

GlobeNewswire April 10, 2017

ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU

GlobeNewswire April 3, 2017

ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

GlobeNewswire March 27, 2017

ProQR to Present at Two Upcoming Investor Conferences in March

GlobeNewswire March 1, 2017

ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update

GlobeNewswire February 28, 2017

On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day

GlobeNewswire February 27, 2017

ProQR to Present at the LEERINK Partners Global Healthcare Conference

GlobeNewswire February 7, 2017

ProQR Announces Results for the Third Quarter of 2016

GlobeNewswire November 14, 2016

Mid-Morning Market Update: Markets Open Higher; Twitter Beats Q3 Expectations

Benzinga.com  October 27, 2016

ProQR Shares Spiking 40%

Benzinga.com  October 27, 2016

ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

GlobeNewswire October 27, 2016